Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:30 pm EST
Share
Senti Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.338 million compared to USD 1.77 million a year ago. Net loss was USD 14.92 million compared to USD 16.64 million a year ago. Basic loss per share from continuing operations was USD 0.83 compared to USD 0.33 a year ago. Basic loss per share was USD 0.34 compared to USD 0.38 a year ago.
For the nine months, sales was USD 2.56 million compared to USD 4.23 million a year ago. Net loss was USD 52.34 million compared to USD 40 million a year ago. Basic loss per share from continuing operations was USD 1.46 compared to USD 1.73 a year ago. Basic loss per share was USD 1.18 compared to USD 1.99 a year ago.
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
SENTI BIOSCIENCES, INC. 
